These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28123130)

  • 1. [Treatment strategy of osteoporosis after the bisphosphonates discontinuation.].
    Soen S
    Clin Calcium; 2017; 27(2):273-280. PubMed ID: 28123130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for osteoporosis--where do we go from here?
    Whitaker M; Guo J; Kehoe T; Benson G
    N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Practice. Postmenopausal Osteoporosis.
    Black DM; Rosen CJ
    N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.
    Rossini M; Orsolini G; Viapiana O; Adami S; Gatti D
    Endocrine; 2015 Aug; 49(3):620-7. PubMed ID: 25649760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do bisphosphonates affect fracture healing?
    Kates SL; Ackert-Bicknell CL
    Injury; 2016 Jan; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate use in children with pediatric osteoporosis and other bone conditions.
    Szalay EA
    J Pediatr Rehabil Med; 2014; 7(2):125-32. PubMed ID: 25096864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
    Verron E; Bouler JM
    Drug Discov Today; 2014 Mar; 19(3):312-9. PubMed ID: 23974069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
    Lems WF; Saag K
    Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of anti-resorptive therapy for osteoporosis.
    Adler RA
    Endocrine; 2016 Feb; 51(2):222-4. PubMed ID: 26433739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
    Lim JS; Jin SH; Kim SB; Lee JI
    J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [[Antiresorptive agents in the treatment of osteoporosis].
    Novak S
    Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate therapy for secondary osteoporosis: adult perspective.
    Reid IR
    Horm Res Paediatr; 2011; 76 Suppl 1():28-32. PubMed ID: 21778745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.
    Guañabens N; Moro-Álvarez MJ; Casado E; Blanch-Rubió J; Gómez-Alonso C; Díaz-Guerra GM; Del Pino-Montes J; Valero Díaz de Lamadrid C; Peris P; Muñoz-Torres M;
    Endocrine; 2019 Jun; 64(3):441-455. PubMed ID: 30963388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intermittent long-term administration of intravenous bisphosphonates for treatment of osteoporosis].
    Miyakoshi N
    Clin Calcium; 2014 Jan; 24(1):93-9. PubMed ID: 24369285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective.
    Boonen S; Ferrari S; Miller PD; Eriksen EF; Sambrook PN; Compston J; Reid IR; Vanderschueren D; Cosman F
    J Bone Miner Res; 2012 May; 27(5):963-74. PubMed ID: 22467094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.